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Lymphoid tyrosine phosphatase and its role in 
autoimmune diseases
The protein tyrosine phosphatase non-receptor type 22 
(PTPN22), also called lymphoid tyrosine phosphatase 
(LYP), is expressed exclusively in hematopoietic cells and 
is a critical gatekeeper of T and B cell receptor (TCR and 
BCR) signaling. In the TCR signaling pathway, LYP acts 
downstream of receptor binding to inhibit the activity of 
key signaling effectors, thereby attenuating T cell activa-
tion. Specifically, LYP has been implicated in the dephos-
phorylation of the positive regulatory tyrosine residue in 
target Src-family protein tyrosine kinases, including FynT 
(Y417) and Lck (Y394). Recent studies have shown that 
LYP is also involved in the modulation of B cell popu-
lations and in their tolerance checkpoints through BCR 
signaling, but its precise mechanisms have not yet been 
established [1,2].
PTPN22 has been identified as a shared susceptibility 
gene for a variety of human autoimmune diseases, includ-
ing type 1 diabetes, rheumatoid arthritis (RA), auto-
immune thyroid disease, systemic lupus erythematosus 
(SLE) and inflammatory bowel disease [3]. Genetic varia-
tion in PTPN22 has been investigated in auto immune 
diseases, but until recently the role of PTPN22 modu-
lation at the mRNA or protein level had not been con-
sidered. Alternative splicing can result in the expression 
of different LYP isoforms and, in a recent study published 
in Genome Medicine, Ronninger et al. [4] reported the 
first evidence of altered expression of PTPN22 splice 
forms in RA.
PTPN22 gene variants and autoimmune diseases
Two missense single nucleotide polymorphisms (SNPs) 
in PTPN22 have been linked with autoimmunity: the 
R620W (C1858T, rs2476601) variant in exon 14, which 
seems to produce a gain of function, resulting in stronger 
negative regulation of T and B cell activation; and the 
R263Q (G788A; rs33996649) change in exon 10, which 
alters an amino acid in the catalytic domain of the 
enzyme, resulting in reduced phosphatase activity [3]. 
These variants have been consistently associated with 
susceptibility to RA, mainly in European populations: it 
is now clear that the W620 allele is one of the most 
consistently associated genetic factors underlying RA 
risk, whereas the Q263 allele acts as a protective factor 
against RA, independent from the R620W variant effect 
(Figure  1) [5,6]. Other studies have suggested that addi-
tional variants in the PTPN22 gene region could influence 
RA susceptibility [7]. Nevertheless, the strong linkage 
disequilibrium (LD) across this region makes it difficult 
to determine whether these associated SNPs are indepen-
dent risk factors for RA or are in LD with the known 
R620W and R263Q variants [8,9].
Since the discovery of the importance of PTPN22 in 
lymphocyte function and its association with many 
autoimmune diseases, there have been several attempts 
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to understand the biological mechanism by which 
PTPN22 gene variants might influence protein activity 
and subsequent changes in cell function. Recent studies 
have shown that the W620 allele (of the R620W variant) 
enhances positive selection of autoreactive B cells, influ-
ences thymic and splenic enlargement, which is accom-
panied by increases in T cell number, and increases 
activation of dendritic cells [1-3]. Moreover, levels of the 
mouse LYP protein homolog (Pep) were observed to be 
dramatically reduced when the equivalent variant to 
R620W (Pep619W) was expressed. It was suggested that 
this could be due to more rapid degradation of the 
Pep619W variant by the calpain 1 cleavage protein than 
of the wild type [2].
PTPN22 splice forms and rheumatoid arthritis
Alternative splicing is a process whereby distinct mRNA 
transcripts are generated from a single gene so that the 
resulting splice variants can be translated into different 
protein isoforms. During this process, a particular exon 
Figure 1. The possible effects of different forms of LYP on rheumatoid arthritis (RA). Left, illustration of LYP isoforms: LYP_v1 has four P motifs, 
but LYP_v2 lacks the P2, P3, and P4 motifs. Healthy patients (top) have a balance of LYP protein isoforms (indicated by the scales and number 
of proteins shown, left); they tend to have a lower frequency of the W620 allele (R620W variant) of PTPN22 and a higher frequency of the Q263 
allele (R263Q variant) (right), which leads to a low risk of RA. Ronninger et al. [4] have shown that the ratio of the long (LYP_v1) and short (LYP_v2) 
isoforms of PTPN22 is significantly higher in RA patients (bottom) than in controls, and RA patients have a higher frequency of the W620 allele and a 
lower frequency of the Q263 allele. These differences might lead to greater inflammation in RA patients.
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can be connected to any of the other exons to form a 
mature mRNA. Hence, the alternative isoforms share 
part of the sequence but not all of it. The PTPN22 gene 
has 11 known spliced mRNAs that putatively encode 
functional proteins, according to the annotation of the 
human genome and transcriptome in AceView [10]. 
Surprisingly, only two splice forms, encoding LYP_v1 and 
LYP_v2, have been well characterized (Figure 1). The first 
encodes an amino-terminal PTP domain, a central region 
of unknown function, and a carboxy-terminal portion 
containing four proline-rich motifs termed P1 to P4. The 
alternatively spliced LYP_v2 has a shorter carboxyl 
terminus, resulting in the absence of the P2, P3, and P4 
motifs [4].
Ronninger et al. [4] have investigated the expression of 
these PTPN22 splice forms in three independent study 
cohorts consisting of Caucasian patients with RA and 
healthy controls. They assessed the mRNA expression of 
the LYP_v1 and LYP_v2 splice forms in peripheral blood 
mononuclear cells (PBMCs) collected from the patients 
and controls. They also sought to determine any corre la-
tion between PTPN22 mRNA expression levels and 25 
SNPs of the PTPN22 gene region, including the R620W 
variant. They found that the expression of LYP_v1 and 
LYP_v2 splice forms in unstimulated PBMCs from RA 
patients was different from that of controls. Cells from 
RA patients showed lower levels of LYP_v2 and higher 
levels of LYP_v1 than cells from controls, and the 
difference was more pronounced when the ratio of ex-
pression of the two isoforms (LYP_v1/LYP_v2) was 
compared between RA patients and controls. Conversely, 
analysis of splice form expression levels in an additional 
cohort consisting of multiple sclerosis (MS) patients 
revealed higher levels of LYP_v2 in MS patients than in 
controls.
To gain insight into the mechanism of differential 
expression of the splice forms, the authors [4] measured 
the expression of LYP_v1 and LYP_v2 in interferon-γ-
stimulated PBMCs from the same RA patients and 
healthy individuals. The expression of splice forms was 
comparable in the stimulated cells, indicating that pro-
inflammatory conditions may directly change the trans-
crip tional profile of PTPN22 splice forms. However, the 
study [4] provided no clear evidence of association 
between the SNPs tested and the expression levels of 
PTPN22 isoforms. The authors speculated that this could 
be due to a lack of statistical power owing to the low 
frequency of PTPN22 risk variants in the population.
The major contribution of the Ronninger et al. study [4] 
is the finding of a correlation between the ratio of the 
splice forms and disease phenotype. These observations 
suggest that the pronounced structural differences 
between these isoforms might affect events involved 
directly in inflammatory processes. Three examples of 
this are as follows. Firstly, T cell behavior is modulated by 
the interaction of LYP with CD2-binding protein-1 (CD2 
is a cell adhesion molecule that influences the efficiency 
with which T cell receptors find a major histo compati-
bility complex (MHC) molecule with an antigenic 
peptide). LYP_v2 lacks several consensus sequences 
described for LYP_v1 that could affect the interaction 
with CD2-binding protein-1. Secondly, the phosphory la-
tion of LYP_v1 may depend on the cell cycle: a consensus 
sequence of the carboxyl terminus of this variant is 
recognized by the cyclin-dependent kinase 1 (CDK1), a 
cell cycle regulatory kinase. This consensus sequence is 
not present in the LYP_v2 isoform, which could have an 
effect on the cell cycle in the lymphoid cells that are 
expressing this isoform. Finally, the LYP_v1 and LYP_v2 
isoforms could interact with different sets of Src 
homology 3 (SH3) domains, because LYP_v1 contains 
four potential SH3 domain binding sites, whereas LYP_v2 
contains only one. However, further studies are needed to 
understand the influence of the differential expression of 
the PTPN22 isoforms, not only in RA, but in other 
autoimmune diseases.
PTPN22 modulation in autoimmune diseases
There is increasing evidence that the same PTPN22 
genetic variants influence several autoimmune diseases, 
but the risk conferred by these variants is not the same in 
each autoimmune disease. The W620 allele increases the 
risk of developing RA and SLE in European populations. 
At the same time, this allele confers protection against 
Crohn’s disease and has no effect in MS. The role of the 
R620W variant seems greater in RA and SLE than in 
systemic sclerosis (SSc). On the other hand, the R263Q 
variant has an important protective role in RA, SLE and 
ulcerative colitis, yet has no effect on genetic predisposi-
tion to SSc.
The results presented by Ronninger et al. [4] have now 
revealed different expression levels of two PTPN22 splice 
forms in RA and MS: the short isoform LYP_v2 was 
found at lower levels in RA patients than in controls, 
where as LYP_v2 was found at higher levels in MS 
patients than in controls. This is in line with the fact that 
MS is not associated with polymorphisms in PTPN22 
and supports disease specificity. Moreover, the ratio of 
the long and short isoforms of PTPN22 was found to be 
significantly higher in RA patients than in controls. 
Collectively, these results suggest that there may be 
complex genetic and immunological mechanisms in 
common underlying these autoimmune diseases.
It is possible that an increased LYP_v1/LYP_v2 isoform 
ratio in RA patients might indicate an activated inflam-
matory process (Figure  1). If this is demonstrated with 
more functional studies, replicated in other cohorts and 
tested in other autoimmune diseases such as SLE, SSc or 
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type 1 diabetes, it could be used together with other 
genetic, immunological and physiological markers to 
improve the diagnosis and treatment of RA, and possibly 
other autoimmune diseases. It has also been hypothesized 
that a selective inhibitor of LYP could revert the negative 
effects of the R620W variant on TCR and BCR signaling, 
and thus might constitute an effective targeted therapy 
for autoimmunity in carriers of the autoimmune-pre-
disposing variant [3]. Although much remains to be 
understood about the genetic variation and regulation of 
PTPN22, the Ronninger et al. study [4] has provided new 
mechanistic insights into the role of PTPN22 splice forms 
in RA, opening up a new avenue of research for under-
standing the genomics of autoimmune diseases.
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